Ultragenyx Pharmaceutical Inc. - 8-K Filing
Ultragenyx completes $210M sale of GENGLYCOS PRV and announces 20% workforce reduction to drive 2027 profitability. (Items: 2.01 Completion of Acquisition or Disposition of Assets, 2.02 Results of Operations and Financial Condition, 2.05 Costs Associated with Exit or Disposal Activities, 9.01 Financial Statements and Exhibits)
Tickers: $RARE